Search

Displaying results 291 - 300 of 2422 in total
  1. Drug

    ATG-101

    go.drugbank.com/drugs/DB17162
    Investigational

    ATG-101 is a novel PD-L1/4-1BB bispecific antibody that was designed to block the binding of immunosuppressive PD-1/PD-L1 and conditionally induce 4-1BB stimulation, thus activating anti-tumor immune effectors

    Synonyms: PD-L1/4-1BB bispecific antibody
  2. Drug

    Sacituzumab govitecan

    go.drugbank.com/drugs/DB12893
    ApprovedInvestigational

    Metastatic triple-negative breast cancer (mTNBC) is an aggressive form of breast cancer with limited treatment options involving cytotoxic chemotherapy agents. Targeted chemotherapy through the application of antibody-conjugated agents (...

  3. Drug

    Gotistobart

    go.drugbank.com/drugs/DB19100
    Investigational

    Gotistobart is under investigation in clinical trial NCT05671510 (ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors).

  4. Drug

    DL-alpha tocopheryl acetate

    go.drugbank.com/drugs/DB14477
    Approved

    Mixtures: PR Natal 430, PR Natal 400
  5. Drug

    PF-04457845

    go.drugbank.com/drugs/DB12012
    Investigational

    PF-04457845 is under investigation in Fear Conditioning. PF-04457845 has been investigated for the treatment of Tourette Syndrome and Cannabis Dependence.

  6. Drug

    PF-04418948

    go.drugbank.com/drugs/DB12024
    Investigational

    Pf 04418948 is under investigation in clinical trial NCT01002963 (A Study To Investigate The Safety And Toleration Of A Single Dose Of PF-04418948 In Healthy Volunteers).

  7. Drug

    Riociguat

    go.drugbank.com/drugs/DB08931
    ApprovedInvestigational

    with group I PAH (pulmonary arterial hypertension) in WHO FC II or III; and for the treatment of patients with inoperable CTEPH (chronic thromboembolic pulmonary hypertension), or persistent/recurrent PH

    Categories: Cytochrome P-450 Substrates, P-glycoprotein substrates
  8. Drug

    Palladium Pd-103

    go.drugbank.com/drugs/DB15016
    Experimental

    Palladium Pd-103 is under investigation in clinical trial NCT00247312 (Pd-103 Dose De-Escalation for Early Stage Prostate Cancer: A Prospective Randomized Trial).

  9. Drug

    Zimlovisertib

    go.drugbank.com/drugs/DB15143
    Investigational

    PF-06650833 is under investigation in clinical trial NCT02609139 (Study to Evaluate Pharmacokinetics of A Modified Release Formulation of PF-06650833 in Healthy Subjects).

  10. Drug

    PF-06821497

    go.drugbank.com/drugs/DB14799
    Investigational

    PF-06821497 is under investigation in clinical trial NCT03460977 (PF-06821497 Treatment Of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma).